In order to boost its dermatology portfolio, Incyte has agreed to acquire Villaris Therapeutics, a biopharmaceutical firm focused on the development of novel antibody therapeutics. Incyte has agreed to pay US$70 M upfront and committed up to US$1.05 B more to develop and commercialise Villaris’ lead asset, auremolimab, an ultra-humanised, anti-IL-15Rβ (CD122) antibody to treat vitiligo. The deal comes less than three months after the FDA approved Incyte’s OpzeluraTM (ruxolitinib) for the treatment of repigmentation in patients with vitiligo.